Physician profile
Aura M Ardon
NPI 1780839787
$3,037.58
in general payments reported to CMS, 2019-2025
20 companies · $1,116 in 2025
The $1,116 reported for 2025 was more than what 87% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $791 · 2021: $20.86 · 2024: $180 · 2025: $1,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,296.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $517.45 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $410.06 | 2019-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $281.45 | 2019-2020 | |
| Abbvie INC. | $250.50 | 2025 | |
| Janssen Pharmaceuticals, INC | $250.44 | 2019-2025 | Spravato |
| Lundbeck LLC | $233.64 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $167.55 | 2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $160.64 | 2024-2025 | Qelbree |
| Allergan, INC. | $141.91 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $127.55 | 2020-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $116.00 | 2019-2020 | |
| Axsome Therapeutics, INC. | $114.21 | 2025 | Auvelity |
| Alkermes, INC. | $54.78 | 2019-2025 | Aristada, Lybalvi |
| Adlon Therapeutics L.P. | $52.00 | 2020 | |
| Jazz Pharmaceuticals INC. | $47.86 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $38.38 | 2019-2025 | Austedo Xr |
| Tris Pharma INC | $23.10 | 2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $19.41 | 2019 | |
| Noven Therapeutics, LLC | $16.07 | 2020 | |
| Currax Pharmaceuticals LLC | $14.58 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aura Ardon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.